MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc CFO & COO Richard Giroux reported selling 56,000 ordinary shares on October 20, 2026, at a weighted average price of $9.95 per share. The sales were made under a Rule 10b5-1 trading plan adopted November 18, 2025. After the sale, Giroux reported direct holdings of 852,530 ordinary shares; additional reported holdings were 5,152 shares held by his spouse and 85,000 held by Aigle Healthcare Partners III LLC.
MeiraGTx Holdings plc officer Richard Giroux reported an intention to sell 56,000 ordinary shares, with an aggregate market value of $557,200. Merrill Lynch is listed as the broker, and October 20, 2026, as the approximate sale date. Giroux also reported selling 56,000 ordinary shares on July 21, 2026, with an aggregate value of $700,560 during the prior three months.
MeiraGTx Holdings plc (MGTX) Chief Sci Ofcr, Ophthalmology Stuart Naylor sold 27,659 ordinary shares on October 6, 2026, at a weighted average price of $10.64 per share. The sales were made under a Rule 10b5-1 trading plan adopted December 9, 2025; individual sale prices ranged from $10.53 to $10.88. Stuart Naylor held 613,187 ordinary shares directly after the sale.
MeiraGTx Holdings plc (MGTX) officer Stuart Naylor reported a proposed sale of 27,659 ordinary shares through Fidelity Brokerage Services LLC. The notice gives an aggregate market value of $294,320.64, an approximate sale date of October 6, 2026, and NASDAQ as the exchange. The shares are listed as arising from restricted stock vesting on January 8 and January 14, 2023. Naylor also reported selling 27,659 ordinary shares on July 7, 2026, with a stated value of $409,558.89.
MeiraGTx Holdings plc (MGTX) director Alan Sebulsky was granted 100,000 restricted share units on September 23, 2026. Each unit converts into one ordinary share upon vesting, with one-third of the award vesting on each of the first, second, and third anniversaries of the grant date. No Rule 10b5-1 plan is reported.
MeiraGTx Holdings plc (MGTX) director Alan Sebulsky reported an indirect holding of 34,500 ordinary shares held by Apothecary Capital LLC as of September 23, 2026. Alan Sebulsky is the LLC’s managing member and may be deemed to share voting, investment and dispositive power over the shares; he disclaims beneficial ownership for Section 16 purposes except to the extent of his pecuniary interest, if any.
MeiraGTx Holdings plc (MGTX) appointed Alan M. Sebulsky as a Class I director effective September 23, 2026. His term expires at the 2028 annual meeting, when Class I directors are up for re-election, and continues until his successor is duly elected and qualified. He will serve on the Science and Technology Committee.
Sebulsky has been Managing Member of Apothecary Capital LLC since its reestablishment in April 2026 and previously was a Partner and Portfolio Manager at Adage Capital Management from July 2012 to April 2026. He is eligible for compensation under the company’s Non-Employee Director Compensation Program. The company expects him to enter its standard director and officer indemnification agreement and reported no related-party transactions with him.
MeiraGTx Holdings plc (MGTX) reported an insider transaction by President & CEO Alexandria Forbes. On 2026-08-18, Forbes sold 62,000 Ordinary Shares of MeiraGTx at a weighted average price of $13.86 per share, in multiple trades between $13.59 and $14.00. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025. After these sales, Forbes directly held 1,325,695 Ordinary Shares of MeiraGTx.
MeiraGTx Holdings plc (MGTX) has a Rule 144 notice filed for the account of Alexandria Forbes covering 62,000 ordinary shares to be sold through Merrill Lynch. The notice lists an aggregate market value of 859,320 for these shares and shows 96,042,996 ordinary shares outstanding, a baseline figure, not the amount being sold.
The shares were originally acquired on 06/07/2018 as an Incentive Compensation Stock Grant from the issuer. The filing also reports that in the past three months, 62,000 ordinary shares were sold on 05/19/2026 for a total of 568,540.
Rubric Capital Management LP and David Rosen report beneficial ownership of MeiraGTx Holdings plc Ordinary Shares in an amended Schedule 13G. They report beneficial ownership of 9,100,000 Ordinary Shares, representing 9.83% of the class based on 92,609,516 Ordinary Shares outstanding as of May 8, 2026. All 9,100,000 shares are reported with shared voting and dispositive power and no sole power. Rubric Capital acts as investment adviser to certain funds and accounts that hold the shares, including Rubric Capital Master Fund LP, which has the right to receive dividends or sale proceeds from more than 5% of the Ordinary Shares. Rosen is identified in his capacity associated with Rubric Capital, and both reporting persons provide a New York business address.